The vast majority of so-called scientific studies focused on cancer research are inaccurate and potentially fraudulent, suggests a new review published in the journal Nature. A shocking 88 percent of 53 “landmark” studies on cancer that have been published in reputable journals over the years cannot be reproduced, according to the review, which means that their conclusions are patently false.
C. Glenn Begley, a former head of global cancer research at drug giant Amgen and author of the review, was unable to replicate the findings of 47 of the 53 studies he examined. It appears as though researchers are simply fabricating findings that will garner attention and headlines rather than publishing what they actually discover, which helps them to maintain a steady stream of grant funding but deceives the public.
“These are the studies the pharmaceutical industry relies on to identify new targets for drug development,” said Begley about the false studies. “But if you’re going to place a $1 million or $2 million or $5 million bet on an observation, you need to be sure it’s true. As we tried to reproduce these papers we became convinced you can’t take anything at face value.”
Begley says he cannot publish the names of the studies whose findings are false. But since it is now apparent that the vast majority of them are invalid, it only follows that the vast majority of modern approaches to cancer treatment are also invalid.
Back in 2009, researchers from the University of Michigan’s Comprehensive Cancer Center also published an analysis that revealed many popular cancer studies to be false. As can be expected, one of the primary causes of false results was determined to be conflicts of interest that tended to favor “findings” that worked out best for drug companies rather than for the people.